Ascelia Pharma AB (ACE.ST)

Nasdaq Stockholm · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), Ascelia Pharma AB reported revenue of SEK 0 and net income of −SEK 80.0M. Annual financial statements are available for fiscal years 2020 to 2024, taken from the company's ESEF annual reports (IFRS).

Open interactive financials →

Key financials

SEK	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31	FY2020 2020-12-31
Income statement
Revenue	SEK 0	SEK 0	SEK 0	SEK 0	SEK 0
Gross profit	SEK 0	SEK 0	SEK 0	SEK 0	SEK 0
Operating income	−SEK 67.8M	−SEK 110.9M	−SEK 147.0M	−SEK 137.9M	−SEK 93.4M
Net income	−SEK 80.0M	−SEK 109.3M	−SEK 131.2M	−SEK 125.9M	−SEK 98.7M
Diluted EPS	−SEK 1.48	−SEK 3.24	−SEK 3.77	−SEK 3.82	−SEK 3.76
Cash flow
Operating cash flow	−SEK 62.8M	−SEK 126.8M	−SEK 125.3M	−SEK 116.6M	−SEK 85.5M
Capital expenditure	SEK 0	SEK 0	SEK 0	SEK 38.0K	SEK 397.0K
Free cash flow	−SEK 62.8M	−SEK 126.8M	−SEK 125.3M	−SEK 116.6M	−SEK 85.9M
Balance sheet
Cash and equivalents	SEK 75.3M	SEK 21.9M	SEK 149.6M	SEK 261.6M	SEK 184.7M
Total assets	SEK 140.9M	SEK 87.1M	SEK 218.6M	SEK 333.5M	SEK 255.4M
Total liabilities	SEK 62.0M	SEK 12.7M	SEK 37.7M	SEK 25.7M	SEK 19.3M
Total debt	–	SEK 0	–	–	–
Shareholders' equity	SEK 78.9M	SEK 74.3M	SEK 180.9M	SEK 307.8M	SEK 236.1M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full ACE.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open ACE.ST financials →